NO20073239L - TNF-antagonister - Google Patents

TNF-antagonister

Info

Publication number
NO20073239L
NO20073239L NO20073239A NO20073239A NO20073239L NO 20073239 L NO20073239 L NO 20073239L NO 20073239 A NO20073239 A NO 20073239A NO 20073239 A NO20073239 A NO 20073239A NO 20073239 L NO20073239 L NO 20073239L
Authority
NO
Norway
Prior art keywords
tnf
polypeptides
treatment
binding
tnf antagonists
Prior art date
Application number
NO20073239A
Other languages
English (en)
Inventor
Thor Las Holtet
Mikkel Holmen Andersen
Mette Munch
Helle Krogh Ottow
Josephus Dirk Nieland
Original Assignee
Anaphore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaphore Inc filed Critical Anaphore Inc
Publication of NO20073239L publication Critical patent/NO20073239L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Sammendrag TNF-bindende polypeptider basert på humane tetranektin C-type lectinliknende domener (TTLD) med forbedret bindingsegenskaper og forbedret effektivitet. Polypeptidene omfatter et TNF-bindende domene med aminosyresekvensen KRWSRYF (SEQ ID NO: l). Det frembringes også fremgangsmåte for å fremstille polypetiden ifølge oppfinnelsen. Polypeptidene kan anvendes for fremstilling av farmasøytiske sammensetninger, og for behandling av et individ som har en patologi mediert TNF, slik som behandling av reumatoid artritt.
NO20073239A 2004-11-22 2007-06-22 TNF-antagonister NO20073239L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62934304P 2004-11-22 2004-11-22
DKPA200401813 2004-11-22
PCT/DK2005/000742 WO2006053568A1 (en) 2004-11-22 2005-11-21 Tnf antagonists

Publications (1)

Publication Number Publication Date
NO20073239L true NO20073239L (no) 2007-08-17

Family

ID=35840156

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073239A NO20073239L (no) 2004-11-22 2007-06-22 TNF-antagonister

Country Status (10)

Country Link
US (1) US7820622B2 (no)
EP (1) EP1824878A1 (no)
JP (1) JP2008520214A (no)
KR (1) KR20070095296A (no)
AU (1) AU2005306168A1 (no)
BR (1) BRPI0518042A (no)
CA (1) CA2587948A1 (no)
NO (1) NO20073239L (no)
NZ (1) NZ555353A (no)
WO (1) WO2006053568A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143274A (en) 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
US20080125580A1 (en) 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
WO2018223118A1 (en) * 2017-06-02 2018-12-06 The Feinstein Institute For Medical Research Use of tetranectin and peptide agonists to treat inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
CA2430953A1 (en) 2000-12-13 2002-06-20 Borean Pharma A/S Combinatorial libraries of proteins having the scaffold structure of c-type lectin-like domains
WO2004000398A1 (en) 2002-06-25 2003-12-31 Medical Patents Limited Injection syringe having a retractable injection needle
EP2311867A1 (en) * 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines

Also Published As

Publication number Publication date
BRPI0518042A (pt) 2008-10-28
KR20070095296A (ko) 2007-09-28
WO2006053568A1 (en) 2006-05-26
EP1824878A1 (en) 2007-08-29
JP2008520214A (ja) 2008-06-19
NZ555353A (en) 2009-12-24
US7820622B2 (en) 2010-10-26
AU2005306168A1 (en) 2006-05-26
US20090155843A1 (en) 2009-06-18
CA2587948A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
NO20073239L (no) TNF-antagonister
JP7440581B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP7007333B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
RU2381233C2 (ru) Агонисты рецептора меланокортина
EA201070623A1 (ru) Конструкция из полипептидов однодоменных антител, применение композиции, ее содержащей, и способ лечения ревматоидного артрита
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
ATE417595T1 (de) Keratin-bindende polypeptide
US20100022446A1 (en) Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
NO20070496L (no) Kimere proteiner og anvendelser derav.
UA105625C2 (uk) Пастка vegf і її терапевтичне застосування
WO2004045553A3 (en) Ca125 gene and its use for diagnostic and therapeutic interventions
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
WO2004069876A3 (en) Trimeric polypeptide construct to induce an enduring t cell response
JP2010501191A5 (no)
HUP0402496A2 (hu) Módosított polipeptidek
MX2021010404A (es) Anticuerpos que se unen a una forma escindida de calreticulina mutante, y agente de diagnostico, preventivo o terapeutico para las neoplasias mieloproliferativas.
MX2012001278A (es) Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
CA2581110A1 (en) Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
ZA202301784B (en) Crf2 receptor agonists and their use in therapy
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes
Wisskirchen et al. Conformational restraints revealing bioactive β‐bend structures for hα CGRP8–37 at the CGRP2 receptor of the rat prostatic vas deferens
DK1448772T3 (da) Fremgangsmåder til forögelse af ekspressionsniveauer af human TNF-receptor
JP2016528231A5 (no)

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application